APR 30, 2015 07:34 AM PDT

New Mechanism Found to Control Cell Response to DNA Damage

WRITTEN BY: Judy O'Rourke
DNA can be damaged by different environmental insults, such as ultraviolet light, ionizing radiation, oxidative stress or certain drugs.

If the DNA is not repaired, cells may begin growing uncontrollably, leading to the development of cancer. Therefore, cells must maintain an intricate regulatory network to ensure that their DNA remains intact. Moffitt Cancer Center researchers have discovered a novel mechanism that controls a cell's response to DNA damage.

The protein SIRT1 plays an important role in controlling DNA damage. It can sense the presence of DNA damage, signal to other proteins that damage exists, aid in the repair of damage and stimulate cell death if the damage cannot be repaired.

Moffitt researchers found that SIRT1 is modified by a process called ubiquitination, in which a small residue called ubiquitin is added to SIRT1. This modification allows SIRT1 to relay information about DNA damage to other proteins, leading to either DNA repair or cell death.

The researchers performed studies to determine how ubiquitin modification changes SIRT1 function. They discovered that cells respond to ubiquitin modification of SIRT1 differently according to the type of environmental insult that occurs. If cells are exposed to a drug called etoposide, SIRT1 ubiquitination blocks cell death. However, if cells are exposed to oxidative stress, SIRT1 ubiquitination promotes cell death.

These results are important because they increase scientists' understanding of how proteins and cells function, potentially leading to more effective therapeutic drugs in the future.

"SIRT1 is known to be abnormally expressed in a variety of cancers and might be a good target for therapy," says Ed Seto, PhD, senior member, Cancer Biology and Evolution Program, Moffitt. "Ubiquitin-proteasome inhibitors have already been successfully used in cancer therapy and clinical trials. Therefore, this research might provide molecular bases and insights for developing additional therapeutic strategies in the future."

The research, in an article titled "Ubiquitinated Sirtuin 1 (SIRT1) Function Is Modulated during DNA Damage-induced Cell Death and Survival," was published in The Journal of Biological Chemistry.

[Source: Moffitt Cancer Center]
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 17, 2019
Cancer
OCT 17, 2019
New hope for ovarian cancer
Ovarian cancer affects roughly 1 in 78 women and although survival rates are high (over 90%) with early diagnosis, we currently do not have a way to test f...
OCT 17, 2019
Microbiology
OCT 17, 2019
A Canine Cancer That Began to Spread From One Dog About 6,000 Years Ago
Dogs can get different kinds of cancers, including one that is transmitted by live cancer cells, which spread through sexual contact....
OCT 17, 2019
Immunology
OCT 17, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
OCT 17, 2019
Genetics & Genomics
OCT 17, 2019
Breast Cancer Drug Increases Survival for Prostate Cancer Patients
A breast cancer drug is better at treating advanced prostate cancer in some men than current therapies, a clinical trial shows....
Loading Comments...